Our Latest News
Featured
Variational AI releases Enki 4: Major update to foundation model for small- molecule drug discovery
Read More: Variational AI releases Enki 4: Major update to foundation model for small- molecule drug discoveryVariational AI introduces Enki™ 4: an improved algorithm and architecture designed to scale, expanding the pre-trained target coverage from 592 to 760 and now applicable to proximity-based therapeutics and novel payloads for antibody drug conjugates. Read More about Variational AI releases Enki 4: Major update to foundation model for small- molecule drug discovery
Blog & Press
Variational AI releases Enki 4: Major update to foundation model for small- molecule drug discovery
Variational AI introduces Enki™ 4: an improved algorithm and architecture designed to scale, expanding the pre-trained target coverage from 592 to 760 and now applicable to proximity-based therapeutics and novel… Read More about Variational AI releases Enki 4: Major update to foundation model for small- molecule drug discovery
Enamine joins Variational AI in Agora Open-Science PRMT6 Discovery Effort
Variational AI is pleased to share that Enamine has joined the Agora Open Science Trust collaboration focused on discovering novel PRMT6 inhibitors for Spinal and Bulbar Muscular Atrophy (SBMA), a… Read More about Enamine joins Variational AI in Agora Open-Science PRMT6 Discovery Effort
Variational AI and Rakovina Therapeutics Expand Collaboration to Accelerate Next-Generation ATR Inhibitors
Variational AI and Rakovina Therapeutics expand their collaboration to advance Rakovina’s kt-5000 series of ATR inhibitors Read More about Variational AI and Rakovina Therapeutics Expand Collaboration to Accelerate Next-Generation ATR Inhibitors
Update: Advancing CNS-penetrant ATR inhibitors with Enki™
Building on their initial hit series, Variational AI and Rakovina Therapeutics share promising new results on ATR inhibitors generated with Enki. The latest findings reveal compounds that balance potency, selectivity,… Read More about Update: Advancing CNS-penetrant ATR inhibitors with Enki™
Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
Variational AI, a generative AI drug discovery company, announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply Variational AI’s Enki™ platform to… Read More about Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
Variational AI & Life Chemicals join forces to discover selective dual EGFR/FGFR1 inhibitors using generative AI
Following their successful 2022 collaboration, which targeted the SARS-CoV-2 main protease, Variational AI and Life Chemicals have partnered for a second time to discover de novo generated selective dual EGFR/FGFR1… Read More about Variational AI & Life Chemicals join forces to discover selective dual EGFR/FGFR1 inhibitors using generative AI
Upcoming Events
VancouverVariational AI to speak at ALL IN Talks West
Variational AI will participate in ALL IN Talks West, an event bringing together researchers, industry leaders, builders, and decision-makers focused on the practical deployment of artificial intelligence systems in real-world environments. “From World-Class Research to Market Impact: Closing the Adoption Gap.” Handol Kim, Co-Founder and Chief Executive Officer of Variational AI, will speak on April
Learn More about Variational AI to speak at ALL IN Talks West
TorontoVariational AI to Participate in the Bloom Burton Healthcare Investor Conference
Variational AI will participate in the Bloom Burton & Co. Healthcare Investor Conference (BBHIC), one of North America’s leading gatherings for healthcare investors and emerging life sciences companies. Meet with Variational AI Handol Kim, Co-Founder and Chief Executive Officer of Variational AI, will attend the conference to meet with investors and discuss the company’s approach
Learn More about Variational AI to Participate in the Bloom Burton Healthcare Investor Conference
- Toronto
Variational AI to Participate in the MaRS Impact Health Summit
Variational AI will participate in MaRS Impact Health, a flagship health innovation event hosted by MaRS Discovery District that brings together entrepreneurs, investors, scientists, clinicians, and policymakers working to advance the future of healthcare. Meet with Variational AI If you are attending MaRS Impact Health and would like to connect with Variational AI to learn
Learn More about Variational AI to Participate in the MaRS Impact Health Summit
BostonVariational AI to Present at PBSS Event on AI and ML in Drug Discovery
Variational AI will participate in the upcoming Boston Pharmaceutical & Bioscience Society (PBSS) event, “Artificial Intelligence and Machine Learning: Shaping the Future of Therapeutic Drug Discovery, Development, and Manufacturing,” taking place April 28, 2026, in Cambridge, MA. This full-day symposium brings together leaders from biotechnology, academia, and pharmaceutical companies to discuss how artificial intelligence and
Learn More about Variational AI to Present at PBSS Event on AI and ML in Drug Discovery
- Vancouver
Variational AI at WebSummit Vancouver 2026
Variational AI is excited to be joining Web Summit Vancouver 2026, one of the world’s premier technology conferences, bringing together over 20,000 attendees, investors, and innovators from across the globe — right here in Vancouver. Handol Kim, Co-Founder and Chief Executive Officer of Variational AI, will participate as a panelist at the event, and Valentin
San DiegoVariational AI at BIO International Convention 2026
Variational AI will be attending BIO International Convention 2026 in San Diego. We’ll be onsite for partnering meetings to connect with pharma and biotech teams interested in accelerating small-molecule programs with generative AI—especially where speed, novelty, and multi-parameter optimization are key. Our delegation will include: Handol Kim, CEO Pete Guzzo, EVP & Head of Drug
Learn More about Variational AI at BIO International Convention 2026
Media & Resources
AI, Drug Discovery & Startups: A Candid Talk with Handol Kim, CEO of Variational AI
In this conversation, Handol shares how his team is rethinking drug discovery using generative AI, tackling one of the most complex and high-stakes challenges in science. From a 25-year career… Read More about AI, Drug Discovery & Startups: A Candid Talk with Handol Kim, CEO of Variational AI
How Generative AI Helped Design a Brain-Penetrant Cancer Drug Candidate (Webinar Recording)
From Handshake to Breakthrough: How Generative AI Helped Design a Brain-Penetrant Cancer Drug Candidate (Webinar Recording) In this 60-minute fireside chat, Rakovina Therapeutics and Variational AI share the story behind… Read More about How Generative AI Helped Design a Brain-Penetrant Cancer Drug Candidate (Webinar Recording)
What’s with RWE Podcast: Generative AI for Drug Discovery
Handol Kim, CEO of Variational AI, shares insights on the growing role of generative AI in pharmaceutical research. The discussion highlights how advanced machine learning approaches can help researchers explore… Read More about What’s with RWE Podcast: Generative AI for Drug Discovery
Variational AI – Emerging Company of the Year
27th Annual LSBC Award – Awards Video – Emerging Company of the Year -Biotech: Variational AI Read More about Variational AI – Emerging Company of the Year